Work

A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Year: 2015

Type: article

Abstract: Milatuzumab is a humanized IgG1K monoclonal antibody that interacts with CD74, leading to rapid internalization and cytotoxicity independent of antibody crosslinking. CD74, also known as HLA class II invariant chain, is a cell-surface antigen expressed on antigen presenting cells (APCs) and involved in pro-survival signaling. Thus, milatuzumab has potential to inhibit APC-mediated T-cell proliferation and decrease the risk of aGVHD. In a xenogeneic SCID mouse model, milatuzumab administered prior to transplant prevented the development of GVHD, suppressed circulating cytokines, and reduced the mortality of the SCID mice (Chen et al, BBMT, 2013).

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2014.11.529